Cite
Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications.
MLA
Rodwin, Benjamin A., et al. “Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications.” American Journal of Medicine, vol. 132, no. 1, Jan. 2019, p. 61. EBSCOhost, https://doi.org/10.1016/j.amjmed.2018.09.026.
APA
Rodwin, B. A., Salami, J. A., Spatz, E. S., Valero-Elizondo, J., Virani, S. S., Blankstein, R., Blaha, M. J., Nasir, K., & Desai, N. R. (2019). Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications. American Journal of Medicine, 132(1), 61. https://doi.org/10.1016/j.amjmed.2018.09.026
Chicago
Rodwin, Benjamin A., Joseph A. Salami, Erica S. Spatz, Javier Valero-Elizondo, Salim S. Virani, Ron Blankstein, Michael J. Blaha, Khurram Nasir, and Nihar R. Desai. 2019. “Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications.” American Journal of Medicine 132 (1): 61. doi:10.1016/j.amjmed.2018.09.026.